Seroprevalence of chlamydia pneumoniae infections among adult with chronic obstructive pulmonary diseases by elisa and immunofluorescence by Jeeva, M
SEROPREVALENCE OF CHLAMYDIA PNEUMONIAE INFECTIONS 
AMONG ADULT WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASES BY ELISA AND IMMUNOFLUORESCENCE 
 
 
 
DISSERTATION SUBMITTED TO 
In partial fulfillment of the requirement for the degree of 
DOCTOR OF MEDICINE IN MICROBIOLOGY  
(Branch IV)M. D. (MICROBIOLOGY) 
of 
THE TAMIL NADU DR. M. G. R MEDICAL UNIVERSITY 
CHENNAI- 600032 
 
 
 
 
 
DEPARTMENT OF MICROBIOLOGY 
TIRUNELVELI MEDICAL COLLEGE 
TIRUNELVELI- 11 
APRIL 2016 
 CERTIFICATE 
 
This   is  to  certify  that  the  Dissertation  “SEROPREVALENCE OF 
CHLAMYDIA PNEUMONIAE INFECTIONS AMONG ADULT WITH 
CHRONIC OBSTRUCTIVE PULMONARY DISEASES BY ELISA AND 
IMMUNOFLUORESCENCE”  presented    herein  by  Dr. M.JEEVA  is  an  
original  work  done  in  the  Department  of  Microbiology, Tirunelveli  
Medical  College  Hospital, Tirunelveli  for  the  award  of  Degree  of  
M.D.( Branch  IV ) Microbiology  under  my  guidance  and  supervision  
during  the  academic  period  of  2012-2015.   
 
 
 
 
The  DEAN 
Tirunelveli  Medical  College, 
Tirunelveli-627011 
 
 
 
 
 
 
 
 
 
 
CERTIFICATE  
 
 
This is to certify that the dissertation entitled “SEROPREVALENCE 
OF CHLAMYDIA PNEUMONIAE INFECTIONS AMONG ADULT WITH 
CHRONIC OBSTRUCTIVE PULMONARY DISEASES BY ELISA AND 
IMMUNOFLUORESCENCE” submitted by Dr. M.JEEVA to the 
Tamilnadu Dr. M.G.R Medical University, Chennai, in partial fulfillment of 
the requirement for the award of M.D. Degree Branch – IV (Microbiology) 
is a bonafide research work carried out by her under direct supervision & 
guidance.   
 
 
 
Dr.C.Revathy. M.D., 
Guide, 
Professor and Head, 
Department of Microbiology 
Tirunelveli Medical College, 
Tirunelveli. 
 
Dr.C.Revathy. M.D., 
Head of the Department, 
Department of Microbiology 
Tirunelveli Medical College, 
Tirunelveli. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DECLARATION  
 
 
 
 I, Dr. M.JEEVA declare that, “SEROPREVALENCE OF 
CHLAMYDIA PNEUMONIAE INFECTIONS AMONG ADULT WITH 
CHRONIC OBSTRUCTIVE PULMONARY DISEASES BY ELISA AND 
IMMUNOFLUORESCENCE.” I carried out this work on at the Department 
of Microbiology, Tirunelveli Medical College, I also declare that this 
bonafide work or a part of this work was not submitted by me or any others 
for any award, degree, or diploma to any other University, Board, either in 
India or abroad.  
 
 This is submitted to the Tamilnadu Dr. M.G.R. Medical University, 
Chennai in partial fulfillment of the rules and regulations for the  
M.D Degree examination in Microbiology.  
 
 
Place: Tirunelveli        
Date:  
 
 
 
 
 
 
Dr. M.JEEVA 
Post graduate student 
MD. Microbiology 
Department of Microbiology, 
Tirunelveli Medical College, 
Tirunelveli. 
ACKNOWLEDGEMENT 
 
I am grateful to The Dean, Dr.Sithy Athiya Munavarah M.D, 
Tirunelveli Medical College and, Tirunelveli Medical College hospital 
Tirunelveli for permitting me to carry out this study. 
I extend my sincere thanks to Prof.Dr.C.Revathy M.D., for her 
valuable guidance and support during the study period. 
I would like to express my sincere thanks to Prof. Dr. S.Poongodi @ 
Lakshmi M.D., for her constant guidance and encouragement given to me 
throughout this study. 
I am highly indebted to Prof. Dr.Ramesh Babu M.D., whose sincere 
guidance and encouragement were a source of strengthfor the successful 
completion of this study. 
I would like to express my sincere thanks to all my Assistant 
Professors Dr.B.Cinthuja M.D., Dr. G.Velvizhi M.D.,                    
Dr. G.Sucila Thangam, M.D., Dr.V.P Amudha M.D., DrI.M Regitha 
M.D., Dr.S.Gowri M.D., Dr.M.Kanagapriya M.D. for their valuable 
suggestions, guidance and support throughout the study. 
I would like to thank all my colleagues,  Dr.T.Sankaranarayanan,  
Dr.S.Suganya, Dr.S.Ummer Sheriff and, Dr.R.Shiny, Dr.R.Poornakala, 
Dr.V.Indhumathi, Dr.S.Prarthana, Dr.P.Anbumathi and 
Dr.R.P.R.Suyambu Meenakshi, Dr.S.Punitha Ranjitham, Dr.V.Uma 
Maheswari, Dr.Ambuja Sekhar and Dr.D.Jeya Ganguli for their support 
and cooperation rendered during the work. 
I extend my thanks to all staff members, Department of Microbiology 
for giving full cooperation and timely help in carrying out the laboratory 
studies. 
Special thanks are due to my Messer V.Parthasarathy, V.Chandran, 
S.Pannerselvam, S.Santhi, S.Venkateshwari. M.Mali, S.Arifal Beevi, 
A.S.AbulKalam, A.Kavitha, T.Jeya, K.Sindhu, K.Umayavel, 
Sreelakshmi and are other supporting staffs for their services rendered. 
 I am greatly indebted to Mr. Heber for his expert guidance in 
statistics. Finally I thank the Almighty for without Him nothing would have 
been possible. I extend my thanks to all the patients for their participation 
and kind co-operation throughout the study period. 
Finally, I extend my wholehearted thanks to my beloved parents, 
friends, family members, my husband Dr.John Amalan M.S., and my 
daughter J.J.Sanvi and my son J.J.Lewin Jaspar for their silent 
sacrifices, support and words of encouragement which were a source of 
inspiration for the successful completion of this study. 
 
 
 
 
 
 
 
LIST OF ABBREVATIONS 
 
C.pneumoniae  - Chlamydia pneumoniae 
C.psittaci          -    Chlamydia psittaci 
CDC                 -    Centers For Disease Control And  Prevention 
COPD               -    Chronic Obstructive Pulmonary Diseases 
DM                    -    Diabetus Mellitus 
HTN                   -   Hypertension 
ELISA                -    Enzyme Linked Immunosorbant Assay 
IgM                    -    Immunoglobulin M 
IgG                     -    Immunoglobulin G 
IgA                    -    Immunoglobulin A 
IIFT                    -   Indirect Immuno Fluorescence Test 
LPS                   -   Lipopolysaccharide 
MOMP               -   Major Outer Membrane Protein 
PCR                   -   Polymerase Chain Reaction 
PBS                   -   Phosphate Buffered Solution 
Th                     -   T helper. 
 
 
 
 
 
 CONTENTS 
Sl.No. Title Page No.
1 INTRODUCTION 1 
2 AIMS  & OBJECTIVES 5 
3 REVIEW OF LITERATURE 6 
4 MATERIALS AND METHODS 29 
5 RESULTS 44 
6 DISCUSSION 66 
7 SUMMARY 75 
8 CONCLUSION 76 
9 BIBLIOGRAPHY  
10 ANNEXURE 
i. Data Collection Proforma 
ii. Master Chart 
 
 
 
 
 
 
ABSTRACT 
Aims: To evaluate the seroprevalence of C.pneumoniae antibodies and its 
relation to the possible association of acute and chronic infection.  
Material / Methods: 50 adults with COPD were tested for serum                      
C. pneumoniae antibodies using the IIFT test and ELISA during their hospitalization. 
Serological diagnosis of acute and chronic C. pneumoniae infection was determined 
and sensitivities, specificities and predictive values of both methods were evaluated 
Results: 46 patients (92%) had serological evidence of C. pneumoniae 
infection. Sensitivity and negative predictive value of ELISA for the diagnosis of                      
C. pneumoniae infection was low when IIFT was used as the gold standard method. 
Chronic C.pneumoniae infection was more common in COPD adult patients. 
Conclusion: C. pneumoniae infection occurs frequently in patients with COPD. 
Immunofluorescence test (IIFT/MIF) is the preferred method for monitoring the 
presence of antibody to this organism. The possible role of chronic C. pneumoniae 
infection in COPD progression needs further investigation. 
Key words: Chlamydia pneumoniae. COPD. IIFT. ELISA. 
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1. INTRODUCTION 
          
Chlamydia pneumoniae is a major pathogen causing respiratory tract 
infection.  C.pneumoniae involves a wide spectrum of respiratory diseases 
including the upper respiratory tract infections like pharyngitis, sinusitis, and otitis; 
also causes lower respiratory diseases, such as acute or chronic bronchitis, chronic 
obstructive airway diseases and pneumonia. It produces infections in both 
immunocompetent and immunocompromised host1,2. C.pneumoniae infections 
have strong possible association with acute exacerbation of asthma and chronic 
obstructive pulmonary diseases (COPD) 3, 4. 
        C.pneumoniae comes under the family Chlamydiaceae. It was first described 
in the year 1986 by Grayston and coworkers. It is an obligate, gram-negative 
intracellular bacterium. This is the third species of Chlamydia, next to 
C.trachomatis, C.psittaci. 
        It has a unique complex biphasic multiplication cycle characterized by 
conversion of the infectious but non-replicating elementary body to the non-
infectious, replicating reticulate body. It produces intracytoplasmic inclusions that 
lack glycogen. 
        The incubation period of C.pneumoniae infection is 3-4 weeks. It can be 
transmitted from person to person by droplet nuclei and close personal contact. It 
appears to be an exclusive human pathogen. No animal reservoir has been 
identified. 
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        Most of the respiratory infections caused by C.pneumoniae are 
asymptomatic and remains as subclinical infection. There is evidence that 
C.pneumoniae often establishes persistent infections and persistence has been 
observed in blood monocytes5. 
        They colonize the epithelial cells of the respiratory tract and promote 
inflammation via the formation of cytokines, such as interleukin-8 and tumour 
necrosis factor-alpha, contributes to disease progression, and is associated with 
severe COPD6-8. It induces Th2 type immune response and may lead to chronic 
infection. 
      In chronic infection it results in serious sequelae like frequent reinfections 
will occur in Chlamydia, so that inflammatory reactions are repeatedly triggered.  
     C.pneumoniae infection has worldwide distribution, with a seroprevalence 
of 40-90% in various populations9. It has been associated with both endemic and 
epidemic occurrences of acute respiratory diseases and responsible for 6-20% of 
all community acquired pneumonias9. The seroprevalence is more in the elderly 
population. 
         For laboratory diagnosis of C.pneumoniae CDC recommends the following 
methods10 
• Cell culture 
• Serology 
• PCR 
   As the cell cultures for diagnosis C.pneumoniae are expensive, time 
consuming, labor intensive and require a specialized laboratory, the clinical 
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usefulness is quite restricted. For cell culture HEP -2 or HL cells in 6, 12, 24 or 96 
wells are used. It needs PCR for confirmation. An average of ≥1 inclusion per 
culture well should be considered a presumptive positive culture. 
        Currently serology is the routine diagnostic technique for detecting recent 
C.pneumoniae infections. 
Immunofluorescence test (MIF)/IIFT: Microimmunofluorescence is the 
standard serological technique. Chlamydia elementary bodies (EBs) are used as 
antigen in MIF test. Chlamydia elementary body is infective form. This MIF/IIFT 
test is mainly useful for the species specific diagnosis and can differentiate 
between IgM, IgG and IgA antibodies9. 
 IgM antibody appers 2-3 weeks after the onset of illness and generally, after 
2-6 months the IgM will not be detectable. IgG antibody response appears 6-8 
weeks after the illness. IgG antibodies indicate either chronic or repeated infection. 
        Acute infection of C.pneumoniae is defined as, a 4-fold rise in IgG or IgM 
titer of ≥16 and past exposure is indicated by an IgG titer of ≥16. Elevated IgA 
titers are main indicators of persisting infection. 
     ELISA was developed to defeat the disadvantages of MIF. It requires less 
time, more objective, easier to standardize, less expensive and can be used for 
large scale of population11. In ELISA lipopolysaccaride is used as an antigen. It 
can detect IgM,IgG and IgA alone or in combination. 
      But both MIF and ELISA can produce false positivity due to their cross 
reaction with other species of Chlamydia. 
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        In complement fixation an enriched lipopolysaccharide (LPS) is used as 
chlamydial antigen. This has been used for many years to detect acute infections 
by C.pneumoniae and C.psittaci. But the sensitivity has been very low, especially 
in reinfection12. Also complement fixation assays are technically difficult. 
Information about the immunoglobulin classes involved in the reaction will not be 
detectable by complement fixation13. 
      Nested PCR is more sensitive. Disadvantage of this PCR is increased risk of 
contamination, reamplification of the products, time consuming nature and high 
cost (CDC). Other PCRs are multiplex PCR, touchdown PCR, hybridization probe 
methods and fluorescent probe- based assays (CDC). 
       The fluorescent probe based assays have the advantages of closed system. 
So, it avoids contamination. These assays are more sensitive and more specific 
than single step PCR.  
      C.pneumoniae is sensitive to macrolides like erythromycin, azithromycin, 
tetracycline, but resistant to sulphonamide groups. DNA based vaccines are 
produced for prevention of C.pneumoniae infections, but only offer partial 
protection or no protection14. 
       The seroprevalence of C.pneumoniae is increasing, hence in the present 
study we determined the seroprevalence of C.pneumoniae specific IgM and IgG 
among adult COPD patients group by the 2 serological methods i.e ELISA and 
IIFT and to evaluate the performance of ELISA with IIFT as gold standard. 
  
            
 
 
 
 
 
 
 
 
Aims  & objectives 
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2. AIMS AND OBJECTIVES 
 
 To detect Chlamydia pneumoniae specific IgM and IgG antibodies by 
indirect immunoflurescence test (IIFT). 
 To detect Chlamydia pneumoniae specific IgM and IgG antibodies by 
enzyme linked immunosorbant assay (ELISA). 
 Comparison and evaluation of these two diagnostic methods for acute and 
chronic diagnosis of Chlamydia pneumoniae infection.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of literature 
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3. REVIEW OF LITERATURE 
 
3.1 History 
          In the initial periods because of their obligate intracellular requirements, 
chlamydial species were believed to be viruses.  Chlamydia pneumoniae was first 
isolated from the eye of a child, in Taiwan during the trachoma vaccine trial. Then 
it was named as TW-18315. Under electron microscopic examination Chlamydiae 
has DNA and RNA, as well as cell wall structures16. Chlamydia pneumoniae 
bacterium was described in 1965. AR-39 isolate was first isolated from a student 
who was suffering from pharyngitis. It was first isolated in the United States and 
was termed as AR-39. This name was given because of its isolation from the acute 
respiratory infection17.TWAR strain transmitted from human to human17. It is an 
exclusive human pathogen. No animal reservoir.  
In Chlamydia genus, the strains are obligate intracellular parasite with 
unique developmental cycle, share genus specific lipopolysaccharides, 
complement fixation antigen. These all criteria fulfill the Chlamydia species. So 
C.pneumoniae was identified as a separate species in 1989 within the genus 
Chlamydia18. 
3.1.1 TWAR: 
   In Sweden, during 1979 to 1992 among 16 young Swedish orienteers, 14 
were suffered from sudden unexpected cardiac death. Most of this death occurred 
during exercising. Their serum were positive for C. pneumoniae antibodies19,20. C. 
pneumoniae  has high sero prevalence in humans. So these deaths are not due to 
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the reason, these young Swedish orienteers donot have a  higher exposure to C. 
pneumoniae. 
3.2 Taxonomy  of Chlamydia 
           The Chlamydiae genus comprises nine species. Two of these were primarily 
human pathogens.  
1) C. trachomatis : causing human pharyngeal, genital and ocular infections 
2) C. pneumonia : mainly causing respiratory disease 
3) C. psittaci : mainly in birds 
4) C. pecorum : this is the 4 th species of this genus produce disease in cattle. 
5) C. abortus : sheep 
6) C. felis : cats 
7) C. suis: pigs 
8) C. caviae : guinea pigs 
9) C. muridarium: mice.   
3.3 Structure of  C. pneumoniae  
3.3.1 Morphology of C. pneumoniae (CP) 
            C.pneumoniae has a pear shaped elementary bodies and also has a loose 
outer membrane. These features morphologically distinguished C.pneumoniae 
from other chlamydial species21. All the isolates of C. pneumoniae doesn’t have 
this pear shaped appearance. C. pneumoniae have a large periplasmic space 
between the outer membrane of C. pneumoniae elementary bodies and the 
cytoplasm22.     
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3.3.2 Peptidoglycan layer of C.pneumoniae 
        C.pneumoniae is similar to Gram negative bacteria. During the reproductive 
cycle of C.pneumoniae, it was appeared to be surrounded by two layers. Even 
though C.pneumoniae is similar to Gram negative bacteria, the peptidoglycan layer 
is not present in the periplasmic space of cell membrane23. Penicillin binding 
proteins, peptide cross links analogues are present in its cell envelope. Chlamydial 
anomaly means, the growth of Chlamydia is sensitive to penicillin, in spite of the 
absence of the peptidoglycan24. Peptidoglycan is produced within the host cell 
during the bacterial growth. Peptidoglycan is necessary for reticulate body cell 
division25, 26.  
3.3.3 Lipopolysaccharide(LPS) 
         Lipopolysaccharide is exposed to the surface, like other Gram negative 
bacteria and present in both elementary body and reticulate body27. LPS is a less 
potent inducer of inflammation28. This is an appropriate marker for Chlamydial 
infections. This LPS is structurally and physiologically not identical with other 
Chlamydial species29.  
3.3.4 Major outer membrane protein( MOMP) 
           Major outer membrane protein was first described in 1981 in C. 
trachomatis30. MOMP has a molecular weight of 40 ×10⁶ and has four variable 
domains like I, II, III, IV. MOMP is the main protein for maintaining the structural 
intergrity of elementary bodies through the disulphide bonds crosslinking. MOMP 
shares several biochemical properties with Chlamydial porins31. MOMP are 
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multifunctional in nature. MOMP of CP was different from C. trachomatis. 
MOMP of CP is a immunogenic proteins32.   
3.3.5 Polymorphic membrane proteins  
          It is also a outer membrane protein, presented on the surface of Chlamydia33. 
This protein contains the genome, which is more significant and approximately 4% 
in C.pneumoniae34. In C.pneumoniae, 21 polymorphic membrane proteins are 
present34. All the 21 polymorphic protein genes of CP to be transcribed and 
produce large proteins like polymorphic protein A, B, D, E, G and H35.  
The production of proinflammatory cytokines, Interleukin- 6 , Interleukin – 8 and 
monocyte chemoattractant protein 1, increased by polymorphic membrane protein 
20 and polymorphic membrane protein 2136.  
3.3.6 Heat shock proteins of C.pneumoniae 
.       In chlamydial pathogenesis, heat shock protein 10, heat shock protein 60 
and heat shock protein 70 are mainly participated in the gene programming37. This 
heat shock proteins are present mainly on the outer membrane complexes of both 
elementary body and reticulate body38. In chlamydial infections antibodies are 
produced against to heat shock proteins, eg heat shock protein 60. Especially heat 
shock proteins 60 production causes localized inflammatory reaction in the uterine 
tubes. 
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3.4 The reproductive cycle of C. pneumoniae 
 
The above picture shows various stages of chlamydiae multiplication cycle. 
           The Chlamydiae has a biphasic exclusive reproductive cycle and has the 
distinct morphological forms. It has three morphological forms 
1) Elementary body 
2) Reticulate body 
3) Intermediate body 
Elementary body is the infectious particle and metabolically inactive. This 
infectious elementary body has a diameter of 200 – 300 nm. Elementary body is 
made up of condensation of nuclear material by the bacterial histone like proteins 
and gene products39, 40. 
Reticulate body has a diameter of 1000- 1500 nm. It is the metabolically 
active form of Chlamydia. Reticulate body comprises homogenous internal 
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material and cytoplasm and made up of granular with diffuse, fibrillar nucleic 
acids41.  
Intermediate body formed during the transmission from reticulate body to 
elementary body. The duration of reproductive cycle of Chlamydia varies from 48-
96 hours. This variation is due to the following factors like infective strain, host 
cells and the environmental source. 
3.4.1 Attachment of elementary body to the host cell 
The receptors and ligands of chlamydia concerned with the linkage of 
elementary bodies to the host cell membranes are still unclear. Most of the initial 
interactions of chlamydial strains and species are interchangeable, electrostatic 
interaction with glycosaminoglycan like heparin sulphate42. Treatment with N- 
glycanase decreased the attachment and inhibit the progression of disease43,44. 
Suggesting that Chlamydial glycans plays an important role in binding of 
elementary bodies into the host cell. The receptors of Chlamydia pneumoniae, 
such as mannose 6 PO₄. Retinoic acid act as an inhibitor of mannose 6 PO₄ 
receptors45, 46. Chlamydial surface antigen such as major outer membrane protein, 
outer membrane protein 2, heat shock protein 70, polymorphic protein D, 
polymorphic protein 2 also have a role in attachment47. 
3.4.2 Adsorption 
Following attachments, elementary bodies are adsorbed into the cytoplasm 
of the host cell. Numerous theories proposed for the entry of elementary bodies 
into the host cytoplasm. One such example is parasite mediates endocytosis 
proposed in 1978 for the entry of C. pneumonia and C. psittaci48. Another entry 
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mechanism is through lipid raft mediated uptake49. Hence the adsorptive step is 
essential for its intracellular survival and its progression. Even though mechanism 
of adsorption is unclear. 
3.4.3 Adsorption (Receptor mediated endocytosis) 
For the adsorption into host cytoplasm, Chlamydia depends on active 
polymerization. After binding to epithelial cells, C. pneumonia produces 
pathological changes in microvilli of respiratory epithelium. Genus Chlamydia is 
responsible to regulate eukaryotic signaling pathway through phosphorylation of 
tyrosine residues of several proteins. Certain signaling pathways guanosine tri 
phosphatases, kinases are involved in the polymerization of actin50. 
3.4.4 Inclusions of Chlamydia 
After adsorption of elementary body into the host cells, it can avoid fusion 
with the host cell, internalization of endosomes and lysosomes51. After the entry of 
elementary body into the host cell, it will be safe within a modified vacuole. 
Morphological forms of elementary bodies are smaller in size and also multiple in 
number. The gene expression of Chlamydia depends on transmission of 
elementary body into the perinuclear region and golgi apparatus52.  
Inclusion proteins were demonstrated in C. psittaci. These inclusion 
proteins were named from inclusion A to inclusion G. Inclusion protein A is found 
in C.psittaci. The functions of inclusion membranes are development of inclusion, 
avoiding fusion with lysosomes  and vesicle trafficking53.  
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3.4.5 Changing of elementary bodies to reticulate bodies and their 
proliferation 
Within the host cell, elementary body differentiates to reticulate body. In 
the host cell, reticulate body reproduction highly shows dependence towards host 
cells for their energy, iron requirement and amino acids within 8 to 12 hours of 
infection. This elementary body changes into reticulate body by their binary fission 
by their host cells. Macrolides class of antibiotics blocks the development of 
reticulate body from elementary body54. Persistent forms are enlarged atypical 
chlamydial forms, which occur due to nutrient deficiency.   
3.4.6 Elementary body exit from the host cell.  
During the multiplication of the elementary body to reticulate body, we can 
detect the intermediate form of Chlamydia. In Chlamydia , after the development 
and multiplication of elementary body, first the inclusion will rupture, then the cell 
membrane ruptures or the host cell lysis will take place55. Then only the 
elementary body released by exocytosis within the host cell. This elementary body 
multiplication initiates new cycles.  
3.4.7 Importance of Iron requirement for the reproduction of Chlamydia  
Iron is an important requirement for most of the pathogenic bacterias56. But 
this iron uptake system is highly complicated. Iron binding siderophores act as a 
major source for this mechanism. It has some limitation also. Some bacteria utilize 
a known uptake system example Mycobacteria. But in Listeria, it has to access the 
cytoplasmic iron from ferritin57. 
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Chlamydia uses the holo- trasferrin for the iron source during its 
developmental process58. The intracellular iron is converted from ferric to ferrous 
form, then it wil be transported into the cytoplasm59. But Chlamydia will escape 
from this early process. So in Chlamydia it can use the iron during the early 
infection endosome, throughout their reproductive cycle. 
3.4.8 Persistence of Chlamydia 
Chlamydia doesn’t have a complete reproductive cycle. It needs some 
essential amino acids, like tryptophan for its completion of reproduction60. But this 
aminoacid is not present in Chlamydia. Secondly, depletion of iron requirement by 
the iron chelators like desferoxamine mesylate also change the Chlamydia 
infections as a persistence ones61,62.  If the Chlamydia enters this state of 
persistence, it cant respond to the antibiotic treatment. And also it may be worse 
and lead to persistence even with the antibiotic treatments like macrolides63. This 
is because of repeated and chronic infections of the Chlamydia species. 
3.5 Pathogenesis of C.pneumoniae 
C.pneumoniae mainly affectsthe bronchial epithelial cells, impairing ciliary 
motility function. Then it produces inflammation via proinflammatory cytokine 
production.this is the main cause for increasing antibody level in above 50 years of 
age. C.pneumoniae produces three types of antibodies like, IgA, IgM and IgG. 
It induces Th2 type of immune response. C.pneumoniae infection induces 
secretion of tumour necrosis factor-alpha by monocytes. It is the main cytokine of 
C.pneumoniae involved in the endothelial and epithelial expression of Interleukin-
1 and adhesion molecules. Tumour necrosis factor alpha produced by the induction 
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of heat shock protein 60. It is mainly depend on concentration and time. Heat 
shock protein 60 induces production of matrix metallo proteinases by the 
macrophages,particularly matrix metallo protein-9. 
C.pneumoniae infection also stimulates nuclear factor-kB. It is the main 
controlling agent for the transcriptional initiation of inflammatory genes8. 
Following are the important proinflammatory cytokines produced during 
C.pneumoniae infection. 
¾ Tumour necrosis factor-alpha 
¾ Interleukin-1 beta 
¾ Chemokines like interleukin-8 
¾ Macrophage chemotactic protein-3 
¾ Adhesion molecules 
¾ Inflammatory enzymes. 
But the level of nuclear factor-kB activity is highly correlated with 
C.pneumoniae infection and dysfunction of lung. 
3.6 Animal models 
In C.pneumoniae animal studies mainly done in coronary artery diseases. 
Along with C.pneumoniae, some other pathogens like herpes simplex virus, 
cytomegalovirus, Helicopylori and dental pathogens can stimulate inflammatory 
responses and contribute to the pathogenesis of atherosclerosis. Animal models 
mainly studied for these agents. Based on this some positive association found 
only with C.pneumoniae and cytomegalovirus. 
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One study showed interaction between C.pneumoniae and murine 
cytomegalovirus in mice and cause development of chronic arterial disease. 
Another study about C.pneumoniae pathogenicity in cardiovascular disease was 
demonstrated in rabbits by intranasal injection with C.pneumoniae. In that study 
cholesterol-rich diet rabbits, showed a quicker development of artherosclerosis, 
also low density lipoprotein and apolipoprotein E deficient in mice infected with 
C.pneumoniae developed hyper chloestereolemia,then develop artherosclerosis. 
3.7 Epidemiology of Chlamydial infection  
C.pneumoniae is a common infection worldwide. About 40- 90% of people 
harboring this C. pneumoniae antibodies worldwide. This also causes community 
acquired pneumonia about 6-20%9. After the age of 6- 8years, C. pneumoniae 
antibody prevalence gradually increases. It can cause both epidemic and endemic 
outbreaks. 
Incubation of C. pneumoniae is 3-4 weeks. C. pneumoniae is an exclusive 
human pathogen. So man is the one of the main reservoir for. It is transmitted by 
droplet nuclei or other respiratory secretions by man to man. No animal reservoir 
for C. pneumonia. 
3.8 Clinical features  
3.8.1 Acute manifestations 
       C. pneumoniae is a intracellular pathogen. It colonises in the respiratory 
epithelial cells and causes asymptomatic infections, remain mild or self restricted. 
It occurs world wide distribution with a seroprevalence up to 70%64.This obligate 
intracellular bacteria can persist in the host. Persisting C. pneumoniae infections 
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are common in the respiratory tract or in atherosclerotic blood vessels65.  In the 
acute infection, C. pneumoniae is transmitted via the respiratory secretions and 
droplets, from person to person66. The incubation period of C.pneumoniae is 3- 4 
weeks. Following are the symptoms and signs of C.pneumoniae. 
Common symptoms are cough, fever, fatigue, and myalgia and presented in 
> 40 percent. Less common symptoms are nausea, abdominal pain and presented 
in 39-11 percent. The uncommon symptoms are chest pain, diarrhea, exanthema, 
arthritis and presented in < 10 percent. In the beginning of infections, pharyngitis 
with hoarseness is present and also causes sinusitis, otitis media, tonsillitis, 
laryngitis and then  developing into more typical bronchitis or pneumoniae. 
Prolonged cough is very common. The period from the onset of infection to 
resolution lasts several weeks.  
3.8.2 Chronic manifestations 
C. pneumoniae infection also causes some chronic manifestations. These 
are chronic bronchitis, bronchiectasis, chronic obstructive pulmonary diseases, 
bronchial asthma. Apart from respiratory infections, it also causes disorders like 
sarcoidosis, multiple sclerosis and reactive arthritis67. And also causes 
development of atherosclerosis, arteriosclerotic plaque formation, coronary heart 
disease,coronary artery stenosis and aortic valve stenosis.  
      In respiratory diseases of C. pneumoniae, smoking is the main predisposing 
factor. Most of the smokers will get chronic obstructive lung diseases by the age of 
50years.  
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Clementsen et al68, studies claim an etiological role of C.pneumoniae in 
asthma in adult patients. It also causes some extrapulmonary manifestations like, 
erythema nodosum,thyroiditis,encephalitis,and the Guillain- Barre syndrome. 
3.9 Risk factors 
3.9.1 Age 
     C.pneumoniae infections considered as a most important cause for elderly 
COPD patients hospitalization in all over the the world. In India, this infection 
affects all the age groups. 
Grayston et al69 studied there is a bimodal age distribution of infection with 
a peak at 8- 9 years and another starting at 70. In northern India Sanjay et al70 
studied in 10 children of persistent asthma with acute exacerbation in the age 
group of 5-14 years. 
    Allegra et al71 studied in adult out patients in range of 17-54 years with a 
mean age group of 42 years. Based on the study Naoyuki et al72 the mean age 
group was 67.6 years, they studied with 205 patients with stable chronic lung 
diseases without ARTIs. 
3.9.2 Sex 
   Sontana et al73 reported that higher prevalence of C.pneumoniae infections 
was found in males than in females, the ratio being 17:1. Marrie et al study 
revealed that the seropositivity rate is usually higher in males. 
    A similar study Georgios et al74 revealed that males showed higher 
prevalence than females. 
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3.9.3 Association of smoking 
     Smoking status increases the prevalence of C.pneumoniae infections among 
COPD patients, particularly in elderly patients. 
     Georgios et al74 studied out of 75 COPD patients, all had history of 
smoking. In Sontana et al73 study showed that among 127 COPD patients 97 were 
smokers. Alyson et al75 study showed that among 392 COPD patients, all had 
history of current or Ex smoking. 
3.9.4 Association of cough 
Chronic persistent cough is the one of the main symptom leading to chronic 
Chlamydia infections. 
Naoyuki et al76 study showed that 366 adult patients with persistent cough 
lasting in excess of 2 weeks. Kwang-Jun Lee et al77 study showed that 137 
students had cough and tested for Chlamydial infections by using ELISA and IIFT. 
3.9.5 Association of breathlessness 
   Difficulty in breathing and its severity is one of the main symptoms in 
COPD patients. 
    Sanjay et al70 studied seroprevalence of Chlamydia pneumoniae infection in 
children from Northern India; they divided mild persistent, moderate persistent, 
severe persistent asthma. 
Blasi F et al, studied seroprevalence in 42 patients with acute exacerbation. 
Georgios et al74 studied among 75 patients, chronic C.pneumoniae infection was 
more common in patients with moderate and severe disease than in patients with 
mild disease. 
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3.10 Laboratory diagnosis of Chlamydia pneumoniae infections 
    With respect to our serology techniques, the detection of current disease is 
hindered by the high prevalence of IgG in elderly patients due to repeated 
asymptomatic infections. Continuous cell culture remains the gold standard for 
demonstrating current infection. But, this technique is complex and has limited 
sensitivity. According to CDC, a positive result should only be declared after 
confirmed by another technique like PCR. Nucleic acid amplification techniques 
are the most sensitive to improve C.pneumoniae detection.(CDC) 
3.10.1 Cell culture: 
         Cell culture is the most widely used technique. But it is a problematic and 
has methodological difficulties, especially from tissue samples, like vascular tissue 
samples. C.pneumoniae is an obligate Gram negative intracellular bacterium. It is 
very essential that C. pneumoniae has to be cultivated within a eukaryotic host 
cells. But the cell culture leads to contamination with other bacterial species eg. 
Mycoplasma. So it is very difficult to grow the C. pneumoniae with cell culture. 
Following specimens can be taken for cell culture: 
     Usually C. pneumoniae causes respiratory tract infections. So we can 
collect the samples like nasopharyngeal swabs, or oropharyngeal swabs, broncho 
alveolar lavage and vascular tissue biopsies. 
Specimen collection: 
        The swabs should be collected with Dacron tip, aluminum or a plastic shaft. 
Swabs like calcium alginate, cotton tips and wooden shafts may inhibit the growth 
of C.pneumoniae. 
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Transport of specimen: 
        All specimens should be cultured within a day (24 hours). If any necessary 
for transportation, it should be kept at 4°C and transported. If not able to culture on 
that day of collection, it should be kept at - 70°C for further processing 
Processing of specimen: 
Swabs taken from the transport medium, compressed along the two sides of 
the tubes  to deliver the extra liquids. Cell lines to be used are Shell vials. We can 
also use HL cells in 6, 12, or 96 well tissue culture plates and HEP- 2.  
Media for cell culture: 
      Eagle´s minimal essential medium, Iscove´s modified Dulbeceo´s medium, 
supplemented with 10% of fetal calf serum, Glutamine, and some non essential 
aminoacids, vancomycin (25µl) and amphotericin B(2µg/ml). 
     Then inoculate the homogenized specimens into a culture medium which 
contains cycloheximide. Then incubate the specimen at 35°C along with 5% CO₂ 
and then see the culture after 3 days. 
      Identification of inclusions: It should be measured by using inclusion 
forming units / ml. this should be done after fixation and staining with a 
monoclonal antibodies, like genus species and species specific antibodies. 
Results: Detection of culture for C.pneumoniae is identification of an 
average of ≥one inclusions per well or tube be considered a “presumptive 
positive”. But always culture should be confirmed by an additional test, like PCR 
and reported as “confirmed positive”. 
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Quality assurance of cell culture: 
       Positive control: C. pneumoniae infected cells. 
       Negative control:  Cells that was not infected by C. pneumoniae.  
Naoyuki et al72, studied in 205 patients with stable chronic lung diseases without 
acute respiratory tract infections. In his study, no positive cases were found with 
cell culture. Kwang-Jun Lee et al77, studied C.pneumoniae infection in an outbreak 
at Korea in the year of March 2004. He was examined 137 students at that 
outbreak. He did serum antibody test for C. pneumoniae using a MIF method and 
ELISA, and nasopharyngeal swab tests to detect the organism by specific PCR and 
culture. They were unable to isolate C.pneumoniae by cell culture. 
3.10.2 Serological methods: 
   C.pneumoniae infection induces IgM, IgG and IgA responses that can be 
detected by serological methods. It provides only a retrospective diagnosis of acute 
infection. So, convalescent serum specimen is needed for showing fourfold 
increase in titer. A paired serum samples are needed for accurate diagnosis. 
Because single IgG titer lack clinical relevance. 
      After C. pneumoniae infections, the IgM antibodies appear first. It occurs 
within 2- 3 weeks of infection. Generally IgM will not be detectable after 2- 6 
months of infection.  Following which Ig G will be increasing and It will be more 
around 6 -8 weeks of infections.   
Advantage of serology test 
• To find out the cause in case of any outbreak 
• Can detect the seroprevalence of infection 
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Main disadvantages of serology test   
• Difficulty in collecting paired serum samples 
• IgG antibody prevalence will be higher in elderly people. 
• No appropriate methods for serology test 
• Also reagents have high quality and are very less. 
The methods used to measure C.pneumoniae specific antibodies vary from 
laboratory to laboratory. So it needs for improvement, standardization of the 
methods and simplification. 
3.10.3  MIF/ IIFT TEST (Immunofluorescence test) 
According to CDC, microimmunoflurorescence (MIF)/IIFT is the method 
of choice for acute C.pneumoniae diagnosis.(32 emerging). It is difficult to 
perform, requires time. It must be subjectively interpreted by an expert with a 
fluorescence microscope. And it also has a inter-laboratory variations. 
       Littman et al78 demonstrated this inter laboratory variations in MIF test by 
compared specific C.pneumoniae IgG and IgA titers in 392 individuals. They 
reported 55% for IgG and 38% for IgA respectively. 
In culture confirmed infection, absent of MIF antibodies has been reported. 
This is more common in young children but rare in adults. 
Mainly used antigen is LPS or MOMP of infected C.pneumoniae 
elementary bodies.. 
• Screening can be done on various dilutions like 1:8 or 1:16. 
Preabsorb serum samples with anti IgG 
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Staining can be done with Evans blue, then counter staining with 
fluorescent labeled antibodies. 
Results: can be read under fluorescent microscope. The recommended 
criteria are four fold increase or greater in Ig M antibody or IgG antibody, that is 
IgM is  ≥  1/16, IgG ≥ 1/ 512. 
Quality assurance:  
• We have to add positive, negative controls and diluted patients serum 
in each step. 
• Ensure the titer of positive control serum for reproducibility between 
each step. 
• Technician should be unaware about the patients/ controls and also 
the status of infection.  
IIFT: samples or labelled antibodies are applied to the reaction fields of a reagent 
tray. The BIOCHIP slides are then placed into recesses of the reagent tray, where 
all BIOCHIPs of the slide come into contact with the fluids, and the individual 
reactions commence simultaneously. These BIOCHIPs are nothing but coated with 
Chlamydia pneumoniae infected cells. This procedure discussed in detail in 
materials and methods. 
Verkooyen et al9 studied 271 COPD patients showed prevalence of 72% of 
IgG with MIF and 53% with r DNA lipopolysaccaride ELISA. 
Kwang Jun-Lee et al78, in his study positive rate of IgM antibody from the 
acute onset was 58%. This percentage became 47% at the convalescent phase. 
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3.10.4 ELISA: developed to overcome the disadvantages of MIF. Because they 
require less time, more objective, easier to standardize. It is based on photometric 
reading of results and expressed in international units.(CDC) 
In ELISA, Chlamydia pneunoniae elementary bodies with LPS are used. It 
is less expensive and easier to use on large scale. So, commonly used in 
seroepidemiological studies. Also it has a higher sensitivity and specificity. 
Elementary body proteins with major outer membrane proteins can also be used in 
ELISA shows species specific reactivity in immunoblot. 
Both MIF and ELISA can produce false positive due to their cross reactivity 
with other species of Chlamydia. 
Detection of human antibodies of the IgG class against Chlamydia 
pneumoniae in serum or plasma for the diagnosis of respiratory disease. (eg- 
COPD, bronchitis,tracheitis, and pneumonia) 
Agarwal A, Chandar Y79 studied about the correlation of chronic 
C.pneumoniae infection and bronchial asthma in serum samples of 60 adults with 
clinical history of asthma at 2008 by ELISA method. In their study 80% of patients 
had IgG anti Chlamydial antibody positive. 
Verkooyen et al9, studied from 271 consecutive COPD patients with mean 
age of 66 and examined the prevalence of chlamydial IgG was 72% with the MIF 
and 53% with the rDNA lipopolysaccaride ELISA. He concluded that rDNA 
lipopolysaccaride ELISA chlamydial assays were most sensitive serological tool 
for diagnosing recent respiratory Chlamydia infections. 
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3.10.5  Complement fixation (CF) 
• CF can identify high levels of antibody in patient serum acquired at 
intervals of 1 week apart 
• It has low sensitivity for identification in re infections. 
Von Hertzen et al7 studied measurement of sputum antibodies in the 
diagnosis of acute and chronic respiratory infections associated with 
C.pneumoniae from 46 patients of COPD. They examined serum specimens, 
sputum, pharyngeal and nasopharyngeal swabs. In their study, sensitivity and 
specificity of enzyme immune assay was 88% and 95% respectively. 
3.10.6 Polymerase chain reaction 
It is a Nucleic acid based amplification technique for C.pneumoniae       
infection. C.pneumoniae can be identified in the following samples by PCR. They 
are (CDC) 
• Respiratory specimens 
• Vascular tissues 
• Serum 
• Pheripheral blood mononuclear cells 
Some times variation can occur between PCRs. This is because of 
collection of serum, extraction of nucleic acids, products of 
amplification.  
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Nested PCR: 
• In this PCR sensitivity rate is high  
• Due to two primer sets are used and two times of 
amplification 
Drawbacks of nested PCR: 
• Contamination is more  
• It will take longer time and high cost. 
Multiplex PCR:   
In this PCR it amplifies >one target sequence in the similar assay. This PCR 
are not so sensitive as compared to target PCR.    For monitoring of PCR assay 
inhibition, internal or amplification controls may be used. We have other types of 
PCR also for the detection of C.pneumoniae infection. These are Hot- star PCR, 
Touchdown PCR, and Hybridization probe –based assays. 
Specimen collection and processing of PCR: 
In a one ml tube containing the transport medium, then centrifuge the tube 
along with the medium, the sediment (pellet) should be used for DNA extraction. 
Vascular or other tissue specimens should be cut into smaller pieces and then do 
the DNA extraction.  
Quality control for PCR: All the reagents and samples taken with clean pipettes.  
3.11 Treatment of C.pneumoniae: 
Most widely used antibiotics are macrolides for C.pneumoniae infection. 
C.pneumoniae is sensitive to azithromycin, tetracycline, doxycyclin quinolones, 
and rifamycins. Because of their anti-inflammatory and antimicrobial properties, 
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macrolides are effective for acute C.pneumoniae infections. These have 80% 
efficacy in respiratory tract infections by C.pneumoniae. But, the persistence of 
C.pneumoniae not related to the development of resistance to the antibiotics. The 
possible explanation may be that the dosage duration and pharmokinetics of the 
treatments were not optimal. 
Blasi et al8, study showed that a group of 42 patients treated with 
azithromycin for 6 weeks, acute exacerbation of C.pneumoniae. Then the serum 
was tested for C.pneumoniae by serological methods showed clearance of 
infection after treatment. 
For atherosclerosis patients treated with azithromycin, roxithromycin, 
clarithromycin. 
3.12 Vaccines for C.pneumoniae: 
DNA based vaccines are available for C.pneumoniae. Immunogenic 
preparations of these vaccines induce antibody production in animals, offer only 
partial or no protection. It is capable of inducing Th1 type immune response. Both 
live and attenuated microorganisms are not desirable; they may produce a 
pathological state.   
 
 
 
  
 
 
 
 
 
 
 
 
Materials and 
methods 
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4. MATERIALS AND METHODS 
 
          The present study was conducted at the Department of Microbiology, 
Tirunelveli Medical College, Tirunelveli from January 2015 to June 2015 to 
evaluate the efficiency of Anti-Chlamydia pneumoniae ELISA IgM and IgG 
antibodies detection and also to compare its performance against Anti-Chlamydia 
pneumoniae IIFT for IgM and IgG antibodies respectively.  
4.1 Study group 
          A total of 50 serum samples were collected from clinically diagnosed as 
chronic obstructive pulmonary diseases in adults.  
4.2 Inclusion criteria  
1. Cough with or without productive. 
2. Phryngitis 
3. Common cold 
4. Difficulty in breathing 
5. Fever for more than 2 weeks 
4.3 Exclusion criteria 
     1. Paediatric age group 
     2. Pregnancy patients 
     3. Bronchiectasis 
  4.4 Ethical clearance 
          Ethical clearance was obtained from the college ethical committee before 
the commencement of the study. 
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4.5 Consent 
       Informed consent was obtained from reliable informants of patients who 
participated in the study.  
4.6 Questionnaire 
 Symptoms regarding the onset of fever & duration, presence of other 
clinical features like cough with expectoration, difficulty in breathing, history of 
smoking and alcohol, diabetes mellitus, hypertension were recorded in the 
questionnaire. 
 History of smoking and alcohol, diabetes mellitus, hypertension, previous 
hospitalization was also included in the questionnaire.  
4.7 Study sample 
       A total of 50 serum samples were collected from the study group. Around 5 
ml of blood sample was collected from suspected cases in the acute phase with 
exacerbation of COPD.  Serum was separated and collected in serum vial .The 
specimen was properly labeled with serial number, name of the patient and date of 
collection. 
4.8 Storage of sample 
         Samples were immediately stored at -80oC for ELISA and 
IMMUNOFLUORESCENCE. 
 
 
 
 
ELISA IgM Kit 
 
 
ELISA IgG Kit 
  
Micro titer plate of ELISA IgM 
 
 
Micro titer plate of ELISA IgG 
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METHODS 
All 50 samples were tested for Chlamydia pneumoniae IgM and IgG 
antibodies   by both   ELISA and indirect immunofluorescence test. 
4.9 Anti-Chlamydia pneumoniae ELISA for IgM 
All the 50 samples were tested by Anti-Chlamydia pneumoniae IgM ELISA 
(EUROIMMUN) 
4.9.1 Principle of the test 
The test kit contains 8 breaks off microtitre strips with 12 rows of strips. 
Each reagent wells coated with Chlamydia pneumoniae antigens, containing with 
lipopolysaccharide and major outer membrane proteins. In the first step of 
reaction, diluted patient samples are incubated with the wells. IgM specific 
antibodies for C.pneumoniae will bind with these antigens, if the sample is a 
positive one. To detect the bound antibodies, a second incubation is carried out 
using an enzyme-labelled anti- human IgM (enzyme conjugate) catalyzing a colour 
reaction. 
4.9.2 Contents of the test kit 
IgM ELISA kit contains the following items to perform the test 
• Microtiterplate wells coated with infected C.pneumoniae antigens. Each 
microplate strips containing 8 individual break-off wells in a frame with 12 
strips and ready for use. 
• Calibrator-(IgM,human),ready for use- dark red 
• Positive control(IgM,human) ready for use-blue 
• Negative control(IgM,human), ready for use-green 
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• Enzyme conjugate is peroxidase-labelled anti-human IgM, which is 
prepared from goat, reddish in colour and ready for use. 
• Sample buffer-containing IgG/RF absorbent (anti-human IgG antibody 
preparation obtained from goat), ready for use 
• Wash buffer-10x concentrate 
• Chromogen/substrate solution-TMB/H₂O₂,ready for use 
• Stop solution-0.5 M sulphuric acid, ready for use 
• Test instruction 
• Quality control certificate 
• Protective foil 
4.9.3 Kit storage 
Don’t freeze the reagents. ELISA kit was stored at +2°C to +8°C. 
4.9.4 Procedure of the test 
All the reagents brought to room temperature (+18°C to +25°C) just about 
30 minutes before use. 
4.9.5 Wash buffer preparation: The wash buffer is prepared with a ratio of 1:9, 
i.e. 10x concentration. Before the dilution, if any crystallization occurs in the 
concentrated buffer, warm the wash buffer to 37°C and mix well. The quantity 
necessary should be removed from the bottle by means of a clean pipette and 
diluted with deionised or distilled water. 
4.9.6 Sample predilution 
 For analysis the patient samples are diluted 1:101 with sample buffer. For 
example, add 10µl sample to 1.0 ml sample buffer and mix up well by vortexing. 
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4.9.7 ELISA procedure 
• Transfer 100 µl of calibrator, positive and negative controls, diluted patient 
samples in to individual microtiterplate wells. 
• The plate was covered with protective foil and incubated for 1 hour at 37°C. 
• Washed three times with diluted   wash buffer 
• 100µl of peroxidase-labelled anti human IgM conjugate to each well. 
• The plate was covered and incubated for 30 minutes at room temperature. 
• Washed three times with diluted wash buffer. 
•  100µl of chromogen / substrate was pipette in to each well. 
• Incubated at room temperature for 15 minutes. 
• 100µl of stopping solution  was pipette to all wells   
• The absorbance of each well was read with in 30 minutes at a wavelength of 
450 nm with a reference wavelength between 620nm and 650nm. 
4.9.8 Calculations of results 
By the recommendation of EOROIMMUN, The upper limit of the reference 
range of non infected persons was define as the extinction value of the calibrator.  
Formula to calculate the ratio 
       Extinction of the control or patient sample / Extinction of calibrator = Ratio 
 4.9.9 Interpretation of results 
• Ratio < 0.8 :negative 
• Ratio ≥0.8 to <1.1:borderline 
• ratio≥1.1: positive 
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Negative result: A negative serological result does not exclude an infection.     
Particularly in the early phase of infection, antibodies may not yet be present or are 
only   present in such small quantities that they are not detectable. 
Borderline result: a secure evaluation is not possible. If there is a clinical 
suspicion and a negative test result, we recommend clarification by means of other 
diagnostic methods or serological investigation of a follow up sample. 
Positive result: It indicates that there has been contact with the pathogen in the 
determination of pathogen-specific IgM antibodies, polyclonal stimulation of the 
immune system or antibody persistence may affect the diagnostic relevance of 
positive findings. Significant titer increase or seroconversion in a follow-up 
sample taken after 7-10 days can indicate an acute infection.  
 
4.9.10 Quality control for IgM 
  Reference value Valid range 
Calibrator O.D 0.400 >0.140 
Pos.control Ratio 2.8 1.5 -4.1 
Neg.control Ratio 0.1 0- 0.7 
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4.10 Anti –Chlamydia pneumoniae ELISA for IgG 
 All 50 samples were tested for detection of IgG antibodies by ELISA 
(EUROIMMUN kit) 
4.10.1 Principle of the test 
    The ELISA test kit provides a semi quantitative or quantitative in vitro 
assay for human antibodies of the IgG class against Chlamydia pneumoniae in 
serum or plasma. The test kit contains 8 breakoff reagent wells with 12 rows 
(8×12=96 wells), which coated with infected C.pneumoniae antigen, containing 
lipopolysaccharide and major outer membrane protein. Diluted patient samples 
were added to the wells and then incubated. If specific IgG antibodies present, it 
will bind to the antigens. To detect the bound antibodies, a second incubation is 
carried out using an enzyme-labelled anti-human IgG (enzyme conjugate) 
catalyzing a colour reaction.  
4.10.2 The test kit contains 
1. A microplate wells coated with antigens -12 × 8 strips 
2. Calibrator 1,200 RU/ml -1× 2 ml 
3. Calibrator 2, 20 RU/ml -1× 2 ml 
4. Calibrator 3, 2 RU/ml- 1× 2 ml 
5. Positive control (IgG, human) - 1× 2ml 
6. Negative control- 1×2 ml 
7. Enzyme conjugate, peroxidase- labelled anti –human IgG - 1× 12 ml 
8. Sample buffer - 1× 100 ml 
9. Wash buffer -1 × 100 ml 
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10. Chromogen/ substrate solution, TMB / H₂O₂ - 1× 12 ml 
11. Stop solution, 0.5 M sulphuric acid -1× 12 ml 
12. Protective foils -2 pieces 
4.10.3 Kit storage 
 Anti Chlamydia pneumoniae IgG ELISA kit was stored at 2 - 8°C 
4.10.4 Test procedure 
Sample predilution 
The test strip wells and other reagents was prepared and brought to room 
temperature. 
Patient samples were diluted 1: 101 in sample buffer. Dilute 10µl serum in 
1.0 ml sample buffer and mix well by vortexing. 
ELISA procedure 
100 µl of the calibrator 2, positive and negative controls and diluted patient 
samples were added in to individual microplate wells. 
Microplate was covered with protective foil and incubated at 37°C for 60 
minutes. 
The wells were washed 3 times with diluted wash buffer solution. 
100 µl of peroxidase – labelled anti human IgG enzyme conjugate were 
added in to appropriate wells of microplate. 
The microplate was covered with protective foil and incubated at room 
temperature for 30 minutes. 
The wells were washed three times with diluted wash buffer solution. 
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100µl of chromogen was pipette in to each well and incubated for 15 
minutes at room temperature. 
100 µl of stopping solution was pipette into each well  
Photometric measurement of the colour intensity was read with in 30 
minutes at a wavelength of 450 nm and a reference wavelength between 620 nm 
and 650 nm. 
4.10.5 Calculation of result 
Calculating a ratio of the extinction value of the control or patient sample 
over the extinction value of the calibrator 2. 
Extinction of the control or patient sample      
= Ratio 
               Extinction of calibrator 2 
 
4.10.6 Interpretation of results 
• Ratio < 0.8: negative 
• Ratio ≥ 0.8 to < 1.1: borderline 
• Ratio ≥ 1.1 : positive 
4.10.7 Quality control for IgG 
  Reference value Valid range 
Calibrator 2 O.D 0.293 > 0.140 
Positive control Ratio 3.8 2.1- 5.5 
Negative control Ratio 0.1 0- 0.7 
  
IIFT – IgM kit 
 
 
IIFT – IgG kit 
 
  
 
Reagent tray of IIFT 
 
 
 
 
 
 
 
 
 
 Appearance of inclusion bodies in Immuno fluorescence 
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4.11 Anti- Chlamydia pneumoniae IIFT for IgM 
         All 50 samples were tested for detection of IgM antibodies by indirect 
immunofluorescence test (EUROIMMUN IIFT KIT) 
4.11.1 Principle of the test 
BIOCHIP coated with infected C.pneumoniae antigen, containing EU 38 as 
a substrate. Incubated with diluted patient samples. If specific IgM antibody 
present, it will bind to the antigens in the BIOCHIPS. Then it will stain with 
fluorescence conjugated antibodies. It can be seen under flurescence microscope.   
4.11.2 Contents of a test kit for 30 determinations 
1. 10 slides, each contains 3 BIOCHIPSs layered with Chlamydia pneumoniae 
infected cells. 
2. fluorecein-labelled anti-human IgM (goat) with Evans blue- 1×1.5 ml 
3. positive control: antibodies against Chlamydia pneumonia (IgM) human -
1×0.1 ml 
4. Negative control: anti Chlamydia species. negative, human -1×0.1 ml 
5. salt for Phosphate buffered solution  pH 7.2 - 2 packs 
6. Tween 20- 2× 2.0 ml 
7. Embedding medium( Glycerol)  - 1×3 ml 
8. Cover classes (62× 23 mm)- 12 pieces 
4.11.3 Kit storage 
The anti –Chlamydia pneumoniae IIFT for IgM kit was stored between + 
2°C and + 8°C. 
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4.11.4 PBS-Tween preparation 
One pack of salt for Phosphate buffered solution was dissolved in 1 liter of 
distilled water and mixed with 2 ml of Tween 20. Stirred for 20 minutes until 
homogenous. It can be stored at +2°C to +8°C, generally for 1 week.  
4.11.5 Predilution of samples 
Diluted the patient samples in 1: 10 dilutions.10µl of sample added to 100 
µl of EUROSORB and mixed thoroughly. The mixture incubated for 15 minutes at 
room temperature. 
Procedure for the test 
• 30µl of diluted patient samples, positive, negative controls were added 
to each reaction field of the reagent tray without any air bubbles 
• The BIOCHIPs slides were fitted in to the corresponding recesses of the 
reagent tray. 
• Incubated for 30 minutes at room temperature 
• The BIOCHIP slides were rinsed with PBS-Tween by using a beaker 
and then immersed in a cuvette containing PBS-Tween for at least 5 
minutes. 
• 25µl of fluorescein-labelled anti-human globulin added to each reaction 
field of a clean reagent tray 
• Then BIOCHIP slides were removed from PBS-Tween, blot with a clean 
paper towel only on back sides and long sides of BIOCHIPs and 
immediately put the slides in to recesses of the reagent tray. 
• Incubated for 30 minutes at room temperature 
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• The BIOCHIP slides were rinsed with a flush of PBS-Tween by using a 
beaker and immersed them in to the cuvette filled with new PBS-Tween 
for 5 minutes. 
• Embedding medium was placed onto a cover glass-maximum 10µl per 
reaction field 
• BIOCHIPs were removed from PBS- Tween and wiped with clean paper 
towel on back and all the four sides of slides.  
• The BIOCHIP slides facing downwards, onto the prepared cover glass.  
• Read the fluorescence with the microscope under objective 20×, 40×, 
with excitation filter: 450-490 nm 
Fluorescence pattern (positive reaction): Antibodies against Chlamydia 
pneumoniae basis a fluorescence of the inclusion bodies located in the cytoplasm 
of infected cells on the test substrate. These inclusion bodies contains densely 
organized elementary bodies (infectious form of Chlamydia, diameter 300 nm) and 
reticular bodies (non-infectious form of Chlamydia, diameter 1000 nm) 
4.11.6 Qualitative evaluation of results 
No reaction at 1: 10 - Negative. No IgM class antibodies against Chlamydia 
pneumoniae detected in the patient sample. 
Positive reaction at 1:10 – Positive. Indicates acute infection. 
4.12 Anti- Chlamydia pneumoniae IIFT for IgG 
All 50 samples were tested for detection of IgG antibodies by indirect 
immunofluorescence test (EUROIMMUN IIFT KIT) 
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4.12.1 Principle  
              BIOCHIP coated with infected C.pneumoniae antigen, containing EU 38 
as a substrate. Incubated with diluted patient samples. If specific IgG antibody 
present, it will bind to the antigens in the BIOCHIPS. Then it will stain with 
fluorescence conjugated antibodies. It can be seen under flurescence microscope.   
4.12.2  Contents of a test kit for 30 determinations 
1. 10 slides, each contains 3 BIOCHIPSs layered with Chlamydia pneumoniae 
infected cells. 
2. Fluorescein-conjugated anti-human IgG (goat) with Evans blue- 1×1.5 ml 
3. 25263. Positive control: antibodies against Chlamydia pneumoniae (IgG) 
human -1×0.1 ml 
4. Negative control: anti Chlamydia species. negative, human -1×0.1 ml 
5. salt for Phosphate buffered saline pH 7.2 - 2 packs 
6. Tween 20- 2× 2.0 ml 
7. Embedding medium( Glycerol)  - 1×3 ml 
8. Cover classes (62× 23 mm)- 12 pieces 
4.12.3 Kit storage 
The anti –Chlamydia pneumoniae IIFT for IgG kit was stored between + 
2°C and + 8°C. 
4.12.4 PBS-Tween preparation 
One pack of salt for PBS was dissolved in 1 liter of distilled water and 
mixed with 2 ml of Tween 20. Stirred for 20 minutes until homogenous. It can be 
kept at +2°C to +8°C, usually for 1 week.  
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4.12.5 Predilution of samples 
Diluted the patient samples in 1: 100 dilutions.10µl of sample added to 
1000 µl of EUROSORB and mixed thoroughly. The mixture incubated for 15 
minutes at room temperature. 
Procedure for the test 
• 30µl of diluted patient samples, positive, negative controls were added 
to each reaction field of the reagent tray without any air bubbles 
• The BIOCHIPs slides were fitted in to the corresponding recesses of the 
reagent tray. 
• Incubated for 30 minutes at room temperature 
• The BIOCHIP slides were rinsed with PBS-Tween by using a beaker 
and then immersed in a cuvette containing PBS-Tween for at least 5 
minutes. 
• 25µl of fluorescein-labelled anti-human globulin added to each reaction 
field of a clean reagent tray 
• Then BIOCHIP slides were removed from PBS-Tween, blot with a clean 
paper towel only on back side and long sides of BIOCHIPs and 
immediately put the slides in to recesses of the reagent tray.. 
• Incubated for 30 minutes at room temperature 
• The BIOCHIP slides were rinsed with a flush of PBS-Tween by using a 
beaker and immersed them in to the cuvette filled with new PBS-Tween 
for 5 minutes. 
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• Embedding medium was placed onto a cover glass-maximum 10µl per 
reaction field 
• BIOCHIPs were removed from PBS- Tween and dry back and all four 
sides with a paper towel 
• The BIOCHIP slides facing downwards, onto the prepared cover glass.  
• Read the fluorescence with the microscope under objective 20×, 40×, 
with excitation filter: 450-490 nm 
Fluorescence pattern (positive reaction): Antibodies against Chlamydia 
pneumoniae basis a fluorescence of the inclusion bodies located in the 
cytoplasm of infected cells on the test substrate. These inclusion bodies 
contains densely organized elementary bodies (infectious form of Chlamydia, 
diameter 300 nm) and reticular bodies (non-infectious form of Chlamydia, 
diameter 1000 nm 
4.12.6 Qualitative evaluation of results  
No IgG class antibodies against Chlamydia pneumoniae detected in the 
patient serum- indicates negative test (at 1:100) 
Positive reaction at 1:100 – Positive. Indicates previous infection. 
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5. RESULTS 
 
5.1 The Study Group 
               A total of 50 adults aged above 30 years who fulfilled the criteria of 
suspected COPD were analysed. This study  was  conducted  at  the  Department  
of  Microbiology, Tirunelveli  Medical College  Hospital, Tirunelveli  over  a  
period  of  6 months  from  January  2015  to  June  2015.  
5.2 Statistical Analysis 
              All the  results  obtained  were  analysed  statistically  for  their  
completeness, consistency  and  accuracy  by  the  parameters  like  mean  and  
percentages. Chi- square test and Fischer Exact test are used. The differences of  
above  parameters  were  tested  by  the  parametric  tests  like  ‘Z’ and ‘t’ and non-
parametric like  x2  tests  test, which  was  applicable  wherever. The  results  of 
ELISA and  IIFT  were  compared  by  Mcnemar’s   x2 test  and  confirmed  by  ‘Z’  
test  of  proportions. The above statistical procedures were performed by IBM 
SPSS Statistics 20. The  P-Values  of  less  than  0.05 were  considered  as  
statistically  significant  (P<0.05). 
5.3 Result Analysis 
      The selected 50 study subjects were analysed based on age and sex, the 
results of the analysis are tabulated in table 1. 
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Table 1.Age and sex wise distribution in study group 
 
Age (in years) Male          Female          Total 
No. % No. % No. % 
< 40 0 0 1 11.1% 1 2% 
41-50 4 9.8% 3 33.3% 7 14% 
51-60 18 43.9% 2 22.2% 20 40% 
61-70 16 39% 3 33.4% 19 38% 
>70 3 7.3% 0 0 3 6% 
Total 41 100% 9 100% 50 100% 
 
Of the 50 patients, 41 were males. Of this, 4 (9.8%) were in the age group 
of 41-50 years and 18 (43.9%) were in the age group of 51-60 years and 16 (39%), 
3(7.3%) were in the age group of 61-70 years and > 70 years. 
   Out of 50 patients, 9 were females. Of this one (11.1%) was in the age 
group of < 40 years and 3(33.3%) were in the age group of 41-50 years, 2 (22.2%) 
were in the age group of 51-60 years,3 (33.4%) were in the age group of 61-70 
years and none above 70 years. 
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FIGURE:1 
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Table 2. Distribution of associated clinical features in study group. 
 
Clinical features No. of patients 
(n =50) 
Percentage 
Cough 36 72% 
breathlessness 50 100% 
fever 3 6% 
 
This table shows (table 2) that among the 50 cases studied, 36 (72%) were 
associated with cough, 50 (100%) had breathlessness, 3 (6%) were presented with 
fever.  
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FIGURE : 2 
 
 
The above figure shows the clinical features, cough, breathlessness, fever 
among study group.  
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Table 3: Smoking history among study group 
 
 
 
 
 
 
 The above table shows smoking history distribution among the 50 subjects. 
Out of this ,35 (70%) were smokers and 15 (30%) were non smoker 
FIGURE : 3 
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Smoker 35 70% 
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total 50 100% 
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Table :4 – frequency of risk factors among study group 
 Risk factor Present Absent 
DM 3 47 
HTN 6 44 
ALCOHOLISM 27 23 
 
 The above table shows among the 50 subjects, 3 were DM and 47 were Non 
DM, 6 were HTN and 44 were Non HTN and 27 we re Alcoholic and 23 were Non 
alcoholic 
FIGURE: 4 
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Table 5: Detection of C. pneumoniae antibodies by IIFT 
 
 
 
 The above table shows that among 46 IIFT positive cases, no one showed 
positive for IgM only, 41 for IgG only,5 for IgM+ IgG. 
 
 
 
 
 
 
 
 
Parameters No of positives Percentage 
IgM  alone 0 0% 
IgG  alone 41 89.13% 
Both IgM + IgG 5 10.87% 
Total 46 100% 
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FIGURE : 5 
 
 
 
The above figure shows 89.13% for IgG and 10.87% for both IgM+IgG.  
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Table 6. Detection of C.pneumoniae antibodies by ELISA 
 
Parameters No of positives Percentage 
IgM alone 0 0% 
IgG alone 42 97.67% 
Both IgM+IgG 1 2.33% 
Total 43 100% 
 
The above table shows among 43 ELISA positive cases , no positives for 
IgM only, 42 were IgG only and only one was positive for both IgM+ IgG. 
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FIGURE: 6 
 
 
 
The above figure shows 98% was IgG and remaining 2% were IgM positives. 
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Table 7. Evaluation of C.pneumoniae  IgM antibody detection by ELISA 
against IIFT 
 
Among the 50 samples tested, 5 were positive for C.pneumoniae IgM antibody 
Detection of Chlamydia pneumoniae  IgM antibody by ELISA was evaluated for 
its sensitivity and specificity against IIFT. 
Sensitivity =    ்௉
்௉ାிே
 =    ଵ
ହ
  ൈ 100 = 20% 
Specificity =    ்ே
்ேାி௉
   =   ସହ
ସହ
  ൈ 100 = 100% 
Positive predictive value (PPV)=  ்௉
்௉ାி௉
 = ଵ
ଵ
 ൈ 100 = 100%  
Negative predictive value (NPV) =  ்ே
்ேାிே
 = ସହ
ସଽ
 ൈ 100 = 92%. 
 From the above table, sensitivity of ELISA test was found to be 20% when 
evaluated against IgM IIFT, as a reference test. Specificity was 100% when 
compared to IIFT and positive and negative predictive values were 100% and 92% 
respectively. According to the Mc Nemer test the p value is > 0.05 which is not 
significant suggests that the ELISA is not more sensitive than the gold standard 
test IIFT. 
ELISA 
IIFT 
Total 
Positive Negative 
Positive 1 0 1 
Negative 4 45 49 
Total 5 45 50 
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Table 8: Evaluation of C. pneumoniae IgG antibody detection by ELISA 
against IIFT. 
ELISA 
IIFT 
Total 
Positive Negative 
Positive 42 2 44 
Negative 4 2 6 
Total 46 4 50 
 
Among the 50 samples tested 46 were IgG antibody positive. 
 Detection of C.pneumoniae IgG antibody by ELISA test was evaluated for its 
sensitivity and specificity against IIFT as a reference test. 
 Sensitivity =    ்௉
்௉ାிே
 =    ସଶ
ସ଺
  ൈ 100 = 91% 
Specificity =    ்ே
்ேାி௉
   =   ଶ
ସ
  ൈ 100 = 50% 
Positive predictive value =  ்௉
்௉ାி௉
 = ସଶ
ସସ
 ൈ 100 = 91%  
Negative predictive value =  ்ே
்ேାிே
 = ଶ
଺
 ൈ 100 = 33%. 
From the above table, the sensitivity of ELISA was 91% when evaluated against 
IgG for IIFT, as a reference test. Specificity was 50% compared to IIFT and 
positive and negative predictive values were 91% and 33% respectively. 
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TABLE 9. Age wise distribution among C. pneumoniae positive cases by IIFT 
 
 
The above table shows that majority of positive cases in the age group of61-
70years.out of 46 positive cases shown by IIFT, only one subject was below 40 
years. Among 51-60 years 17 were positives by IIFT. 
 
 
 
 
 
 
 
 
Age in years Positive cases Percentage 
≤ 40 1 2% 
41-50 7 15% 
51-60 17 37% 
61-70 18 39% 
> 70 3 7% 
Total 46 100% 
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FIGURE: 7 
 
 
 
 The above figure shows, among the 46 positive cases by IIFT 37% were in 
the age group of 51 – 60 years and 39% were in the age group of 61 – 70 years. 
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TABLE :10- Sex wise distribution among C. pneumoniae  positive cases by 
IIFT 
 
 
Sex wise distribution of Chlamydia pneumonia positive cases in the above 
table shows that males are more affected  than  the females. Out of 46 positive 
cases detected by IIFT 38 were males and 8 were females. The ratio of male to 
female was found to be 4.8:1 
 
 
 
 
 
 
 
Sex Positive cases Percentage 
Male 38 82.61% 
Female 8 17.39% 
Total 46 100% 
60 
 
 
 
FIGURE:8 
 
 
 
The figure shows that out of 46 positive cases detected by IIIF 83% were 
males and 17% were females. 
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Table 11- Association of smoking among C. pneumoniae positive cases by IIFT 
Risk factor 
Positive Negative 
Smokers 
(n=35) 33 2 
Non smokers 
(n=15) 13 2 
 
Association of smoking in Chlamydia pneumoniae positive cases is shown 
in the table. Out of 46 positive cases detected by IIFT 33 cases had H/O smoking 
whereas 13 were Non smokers. According to fisher´s exact test the p value was 
0.574. It was found to be statistically non significant. 
FIGURE: 9 
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Table 12: Association of cough in  C. pneumoniae positive cases by IIFT 
Cough Positive Negative 
Present 
(n=36) 32 4 
Absent 
(n=14) 14 0 
  
The above table shows that out of 46 positive cases, 32 patients were 
presented with cough and remaining 14 patients did not have complaining of 
cough. According to fishers exact test the p value was 0.566. it was found to be 
statistically non significant. 
FIGURE: 10 
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Table 13: Association of  dyspnoea in C. pneumoniae  positive cases by IIFT 
   Dyspnoea 
Positive Negative 
Dyspnoea 
Present 
(n=50) 46 4 
  
Absent 
(n=0) 0 0 
 
The above table shows that among 46 positive cases, all the 46 patients had 
difficulty in breathing. 
Table 14: Association of fever in C. pneumoniae  positive cases by IIFT 
  Fever 
Positive Negative 
Fever 
Present 
(n=3) 3 0 
Absent 
(n=47) 43 4 
 
The above table shows that, out of 46 positive cases, 3 had fever and 
remaining 43 didn´t have fever. According to fisher´s exact test the p value was 1. 
It was found to be statistically non significant. 
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FIGURE:11 
 
 
Table : 15- Association of risk factors in C. pneumoniae positive cases by IIFT 
Risk factor Positive Negative 
DM 3 0 
HTN 6 0 
ALCOHOLISM 25 2 
 
 Table 15 shows, among 46 positive cases 3 had DM, 6 had  HTN and 25 
were Alcoholic. 
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FIGURE : 12 
 
 
 
 The above figure shows distribution of risk factors, like DM, HTN and 
Alcoholic among the 46 positive cases by IIFT. 
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6. DISCUSSION 
 
          Chlamydia pneumoniae is a respiratory pathogen, and most people are 
infected by the age of 10 years70. Many studies have shown that the antibody 
prevalence rises with age in adult populations. C. pneumoniae causes upper and 
lower respiratory tract infections in humans and causes about 10% of the 
pneumonia cases in adults worldwide5. Persistent C. pneumoniae infections have 
been associated with several chronic diseases, such as asthma and chronic 
obstructive pulmonary disease. After an acute infection, IgM titers usually fall 
within 2 months and normalize within 4 to 6 months. Elevated IgG levels may 
persist for several years and occasionally be detectable over 3 years after the acute 
infection, elevated IgG antibodies may also indicate on going chronic infection. 
              In this study, examined the possible role of C. pneumoniae in episodes of 
acute exacerbation of COPD. In the present study it was demonstrated that 
approximately 10.9% of the COPD patients had serological evidence of acute             
C. pneumoniae infection at the time of exacerbation by using the combination of 
the IIFT test and ELISA and that chronic C. pneumoniae infection was also 
common. Since direct isolation of C.pneumoniae is difficult, serology plays an 
important role in confirming C.pneumoniae infection. The IIFT test is generally 
accepted as the gold standard for the serological diagnosis of C.pneumoniae 
infection. However, interpretation of specific and non-specific fluorescence 
patterns requires experience and skill, and the interpretation is very difficult and 
subjective. In addition, cross-reactions between C. pneumoniae and other 
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Chlamydial species have been reported. The result of the study showed that C. 
pneumoniae IgG antibody is suggestive of persistent infection was significantly 
more in elderly with COPD patients. Several studies in adults have shown that the 
association between the presence of C.pneumoniae IgG antibody seropositivity and 
chronic persistent asthma80,81. The possible mechanisms to increase the severity of 
COPD may be the result of increased production of inflammatory cytokines. 
6.1 Age and sex wise distribution in study group 
       The present study shows that out of 50 suspected cases, males are found to 
be predominant than the females in the ratio of 4.6:1.       
Male preponderance was also observed in similar studies conducted by 
Sonata et al73.  Smoking is observed more among males than females and it is a 
known risk factor for development of COPD. Majority of the suspected COPD 
cases in the study group belong to the age group of 51-70 years in the present 
study. This result is similar to the study conducted by Allegra et al71. 
       The prevalence of C.pneumoniae infection depends on the subject’s age, 
geographic area of residence and the prevalence of other chronic diseases. 
Endemicity of C.pneumoniae infection is more in Asia than in Western countries3. 
6.2 Distribution of associated clinical features, laboratory findings in study 
group: 
      The present study shows that among the 50 C.pneumoniae suspected cases, 
100% was associated with dyspnoea, and 72% with cough and 6% had fever. 70% 
were smokers, 54% were alcoholism, 6% were DM, 12% were HTN, and 46% 
were associated with X-ray findings. 
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         This was similar to the study conducted by Georgios et al74 and in contrast 
to a study by Sanjay et al 70. Georgios et al74, study showed among the 75 COPD 
patients, all were associated with dyspnoea, 55% were smokers, 84% with cough. 
In David et al82, study revealed that among 147 patients 87% with dyspnoea, 44% 
were smokers and 11% had fever. 
6.3 Detection of C.pneumoniae antibodies by IIFT: 
   In the present study among the 50 patients tested, 46 were found to be 
C.pneumoniae antibody positive by IIFT. Among the 46 positive cases, none were 
positive for IgM antibodies alone, whereas 41 cases were positive for IgG and 5 
were positive for both IgM and IgG antibodies. Cells infected with C.pneumoniae 
are used as antigen for IIFT. 
In his study, Kwang-Jun Lee et al77 among 19 patients in acute phase, 
11(58%) were positive for IgM and 5(26%) were positive for IgG. However 
Sanjay et al70, studied among 54 patients, 26 were positive for IgG and no positive 
cases for IgM.   
6.4 Detection of C.pneumoniae antibodies by ELISA: 
      The present study shows 43 ELISA positive cases among the 50 cases 
tested. among them, 42 (97.67%) were positive for IgG antibodies only, one 
(2.33%) for IgM+IgG and there were no IgM alone positives cases.  
       In a similar study conducted by Verkooyen et al9 among showed that out of 
125 ELISA positive cases, all the 125 were positive for IgG antibody only. None 
of the cases were positive for IgM antibody.   Agarwal A, Chander Y79 studied 
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among 60 patients for C.pneumoniae ELISA, all the 60 were positive for IgG and 
no positive cases for IgM. 
6.5 Comparison of positivity by ELISA and IIFT in detection of 
C.pneumoniae infection: 
      The positivity rate of ELISA was 86% and it was 92% by IIFT. In the 
present study C.pneumoniae infection was found in 92 % of adult patients with 
COPD.  
       In a Norethern india study done by Sanjay et al70, observed that the 
prevalence of C.pneumoniae was 40.62%. And there was a high prevalence of 
C.pneumoniae 85.5% in elderly group conducted by Sontana et al 73. 
6.6 Evaluation of ELISA against IIFT as gold standard: 
      The Chlamydia ELISA used in this study is based on chlamydial LPS and 
MOMP antigens intended for the detection of serum anti-LPS IgG, and IgM 
antibodies in patients with chlamydial infections. The advantages of these tests 
over IIFT and culture include reproducibility, objective analysis, and short 
performance time. However, this test cannot differentiate between chlamydial 
species due to the genus-specific nature of chlamydial LPS. 
        The sensitivity of C.pneumoniae IgM ELISA was 20% when evaluated 
against IIFT, as a reference test. Specificity of ELISA was 100% compared to IIFT 
and positive and negative predictive values were 100% and 92% respectively. The 
sensitivity of C.pneumoniae IgG antibody ELISA was 91% while the specificity 
was 50% when evaluated against IIFT.  
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      The sensitivity calculated from this study is in contrast to the study 
conducted by Gutierrez et al at 2001. Similar low sensitivity and high specificity 
for ELISA was reported by Kenneth Person et al83 at 2000 with 36% sensitivity 
and 95% specificity. Hence all the samples negative by ELISA have to be 
confirmed by a more sensitive test like MIF/IIFT or PCR. 
6.7 Evaluation of C.pneumoniae IgM antibody by ELISA and IIFT: 
     IgM antibody appears 2-3 weeks after the onset of illness and generally, 
after 2-6 months the IgM will not be detectable. 
IgM antibody was detected in 5 cases by IIFT and in one case by ELISA. 
All these patients also had coexistent IgG antibodies. In a similar study conducted 
by Verkooyen et al9 among COPD patients out of 125 ELISA positive cases, none 
of the cases were positive for IgM antibody. 
    Kwang-Jun Lee et al77 observed that 48% of the study population was 
positive for IgM antibodies at the acute phase of respiratory tract infections in 
Korea, and 16% were positive during the convalescent phase. Sontana et al73 
revealed that only 4% had IgM in their serum during exacerbation of COPD. 
     The difference in sensitivity and specificity of IgM based assays may be 
because they are strongly influenced by the quality of the antigen used and vary 
greatly between commercially available products. 
 6.8 Evaluation of C.pneumoniae IgG antibody by ELISA and IIFT: 
    A delayed IgG response appears 6-8 weeks after the illness. IgG antibodies 
can indicate either chronic or repeated infections. C.pneumoniae IgG antibodies 
were detected in 46 patients by IIFT and 43 patients by ELISA.  
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    In a Similar study Sontana et al73 revealed high prevalence of 
C.pneumoniae IgG (75.8%) among the study group. A study done in 
Madyapradesh by Agarwal et al79 in 2008 revealed that C.pneumoniae IgG 
antibody positivity rate in patients with bronchial asthma was significantly high 
(80%). A high prevalence of IgG was reported in a study population by Seattle, in 
the United States of America (73%) . 
     IgG antibodies have been shown to persist for long periods and decline very 
slowly. This higher prevalence may be due to bronchial hyper responsiveness to 
the C.pneumoniae antigen. High levels of IgG antibodies are of diagnostic value in 
chronic chlamydial infection. 
6.9 Age wise distribution among positive cases: 
     The present study shows that majority of positive cases are in the age group 
of 61-70 years. Out of 46 positive cases shown by IIFT, 35(76%) were in the age 
group of elderly peoples. 
    Agarwal et al79 (80%) and Sontana et al73 (86.4%) also reported the similar 
results in which elderly age groups forms the majority of positive cases. However, 
Sanjay et al70 revealed that seroprevalence of C.pneumoniae is higher in asthmatic 
children in the age group of 5-14 years conducted at PGIMER, Chandigarh at 
2002. 
   This high prevalence in elderly peoples in this study may be due to repeated 
infections of C.pneumoniae, risk factors like DM, decreased immunity and it leads 
to persistence of infections.  
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6.10 Sex wise distribution among positive cases: 
      Sex wise distribution of C.pneumoniae positive cases in the present study 
shows that males are more affected than the females. Out of 46 positive cases 
detected by IIFT, 38(82.6%) were males and 8 (17.39%) were females in the ratio 
of 4.8:1. 
      Sontana et al73 also showed similar results where males are more 
predominant than the females in the ratio of 17:1. Seropositivity rate was higher in 
males as revealed by Grayston et al 69. 
     High prevalence among males is probably due to more outdoor activities by 
males in comparison to females which results in more exposure to infection. 
6.11 Association of smoking in positive cases: 
Smoking is a main predisposing factor in COPD patients causing 
C.pneumoniae infection.  In the present study out of 46 positive cases 33 (71.7%) 
were smokers and 13(28.3%) were non smokers. Cigarette smoking had the higher 
rate of infection with C.pneumoniae. Smoking is well known important risk factor 
for COPD patients through alteration in mechanisms of the host defense system. In 
the present study, there was association found between smoking and 
C.pneumoniae infection.  
    In  contrast  Ruiz et al study in 1999 which was reported that there was no 
association between the cigarette smoking and infection due to atypical bacterial 
pathogens especially C.pneumoniae. 
       Sontana et al73 (11) studied among 127 COPD, 97 patients had H/O of 
smoking and the seroprevalence of C.pneumoniae was detected as 96.1%. This 
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prevalence was higher among smokers when compared with non smokers. In 
contrast Naoyuki et al76 studied among 366 COPD adults 240 were smokers and 
showed 24% prevalence. 
6.12 Association of cough in positive cases: 
       In the present study out of 46 positive cases, 32 (69.5%) presented with 
cough and 14 (30.43%) did not present with cough. 
        C.pneumoniae is a well-known cause of persistent cough in both children 
and adults. Naoyuki et al 76 showed that about 20% of patients presented with 
cough lasting for more than 2 weeks had serological evidence of acute 
C.pneumoniae infection. It may be accountable for a substantial proportion of 
prolonged coughing illnesses. Positivity rate by IIFT was 38% among children 
with persistent cough. 
       In contrast Birkeback et al in 2000 detected only 3 out of 201 adult patients 
with chronic coughs by C.pneumoniae. Kwang-Jun Lee et al77 studied 
C.pneumoniae prevalence among 137 students and demonstrated that72 (58.3%) of 
them had cough. 
6.13 Association of dysponea in positive cases: 
       In the present study, out of 46 positive cases, all patients had difficulty in 
breathing.  
       In a similar study by Georgios et al74 among the 75 COPD patients, 93% of 
patients who showed difficulty in breathing had serological evidence for 
C.pneumoniae infection.  
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6.14 Association of fever in positive cases: 
     The present study showed, among the positive cases only 3(6.5%) had 
fever.   
   A similar study by Sontana et al73 showed that among 127 elderly COPD 
patients, the seropositivity rate was 96.1% and only 3.9% positive cases presented 
with fever. David et al82 studied seroprevalence of CP infection among 147 adult 
men, among this 11% of positive cases presented with fever.  
       The present study shows an increase in positivity when a single serum from 
the patient was subjected to a combination of ELISA and IIFT rather than 
subjecting to ELISA.  
      Thus in this study an increase in detection of C.pneumoniae infection when 
both IgG and IgM antibodies were tested. ELISA was found to be less sensitive 
than IIFT. IgG antibodies were more prevalent than IgM antibodies and also found 
to be high among the elderly age group. This could indicate a chronic persistent 
C.pneumoniae infection among the tested COPD patients. 
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7. SUMMARY 
 
• In the present study 46 cases were positive for C.pneumoniae by IIFT.  
• In the present study 43 cases were  positive for C.pneumoniae by ELISA. 
• Sensitivity, specificity, PPV, NPV for IgM antibody was 20%, 100%, 100% 
and 92% respectively. The sensitivity, specificity, PPV, NPV for IgG 
antibody was 91%, 50%, 91% and 33% respectively. 
• In the present study C.pneumoniae infections were more common in the age 
group of 51-70 years. 
• C.pneumoniae infections more in males (83%) when compared to females 
(17%) with a male: female ratio of 4.8:1. 
• The C.pneumoniae infection rate was highest in patients presented with 
H/O smoking (72%). 
• In the present study majority of C.pneumoniae infections were common 
with patients having coughs more than 2 weeks (70%). 
• In the present study C.pneumoniae infections were more common among 
the patients with severe grade of dyspnoea (92%). 
• Fever was a less significant symptom among the C.pneumoniae infections 
(6.5%). 
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8. CONCLUSION 
 
• Our preliminary data represent the first evidence of association between 
C.pneumoniae infection and COPD in our area. 
• This study highlights the high prevalence of C.pneumoniae infections 
among adult COPD patients. 
• C.pneumoniae infection was found to be particularly high in the elderly 
groups.  
• This suggests that it plays a substantial role in causing acute or chronic 
persistent infections in COPD patients. 
• ELISA was found to be less sensitive than IIFT, but with the cost 
constrains, ELISA test is very simple, easy and cost effective that can be 
easily adopted in the clinical laboratory. 
• These C.pneumoniae infections may make a significant contribution to 
morbidity in COPD patients. Further studies are needed to define more 
effective treatment strategies. 
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Annexure 
 
 
SEROPREVALENCE OF CHLAMYDIA PNEUMONIAE INFECTIONS 
AMONG ADULT WITH CHRONIC OBSTRUCTIVE PULMONARY 
DISEASES BY ELISA AND IMMUNOFLUORESCENCE 
PROFORMA 
Name     : 
Age / Sex    : 
Occupation    : 
Address    : 
Clinical Diagnosis   : 
Present Complaints 
H/O Fever & Duration  : 
H/O Cold    : 
H/O. Cough & Duration  : 
H/O Difficulty in Breathing : 
Past History : 
 
General Examination 
DM  Non DM  
HT  Non HT  
Alcoholic  Non Alcoholic  
Smoker  Non Smoker  
 
 
 
 
 
CVS      : 
RS     : 
CNS     : 
Investigation : 
TC DC ESR Hb 
    
 
X-Ray Findings : 
 
Results  ELISA    IgM :  IgG : 
  IMMUNOFLUORESCENCE IgM :  IgG : 
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1 60 MALE Coolie P 2 weeks P III N N N P N P P P N 0.074 P 0.9112 N P
2 81 MALE Agricutural worker P 1 P III P N N N N N N N N 0.0271 P 0.8622 N P
3 63 MALE Coolie P 1 P 1 II N P N N N P N N N 0.0265 P 1.175 N P
4 65 MALE Coolie P 12 P 12 II N P P N N P P P N 0.0556 P 0.9242 N P
5 65 MALE Coolie P 5 D P 5D II N P P P P P N N N 0.1244 P 1.0468 P P
6 74 MALE Unemployee P 2 P 2 III N P P P P P N N N 0.2054 P 0.3297 N P
7 65 MALE Coolie P 1 P 1 II N P P N N N N N N 0.0392 P 0.8785 N P
8 63 MALE Coolie N P 5D III N P P N N P N N N 0.0607 P 0.4909 N P
9 67 MALE Coolie P 4 W P 7D II N P P N N N N N N 0.0432 P 0.9994 P P
10 60 MALE Coolie P 4W P 4W III N P N N N N N N N 0.0589 P 1.3554 N P
11 60 MALE Coolie P 10D P P N N N N N N N N 0.0505 P 1.2607 N P
12 69 MALE Coolie P 1 W P 1W III P P P N N P N N N 0.05 P 0.9311 N P
13 65 MALE Coolie P 2W P 2W II N P P N N N P P P 0.5666 P 0.8115 P P
14 45 MALE Coolie P 4W P 2W II N P P N N P N N N 0.025 P 0.5338 N P
15 60 FEMALE House wife P 1W P 1W II N N N N N P N N N 0.1885 N 0.2352 N N
16 60 MALE Farmer P 1W P 1W III N P N N N N N N N 0.1637 P 1.0001 N P
17 63 MALE Coolie P 3W P 8W III N P N N N N N N N 0.0905 P 0.966 N P
18 59 MALE Coolie P 24W P 24W III N P P N N P N N N 0.0799 P 1.2649 N P
19 60 MALE Farmer N P 2 Y III N P P N N N N N N 0.111 N 0.2906 N P
20 60 MALE Coolie P 1W P 1W III N P P N N N N N N 0.0444 P 1.1256 N P
21 59 MALE Coolie P 10D P 10D II N N N N N N N N N 0.1689 P 0.8353 N P
22 69 MALE Farmer N P 7 Y III N P P N N P N N N 0.025 P 1.2745 N P
23 50 MALE Mill worker P 2W P 10Y III N P N N N P N N N 0.0559 P 0.9616 N P
24 54 MALE Farmer N P 6Y III N P P N N P N N N 0.0649 P 1.1738 N P
MASTER CHART
25 65 FEMALE Home Maker P 3W P 3W III N N N N N N N N N 0.0632 P 0.747 N P
26 56 MALE Coolie N P 8Y III N N N N N N N N N 0.061 P 1.0636 P P
27 67 MALE Farmer N P 5Y III N P N N N P N N N 0.0707 P 0.9026 N P
28 51 FEMALE Home Maker P 2W P 3Y III N N N N P P N N N 0.0472 P 0.7497 N P
29 54 MALE Watchman N P 28W III N P P N N P N N N 0.0368 P 0.9305 N P
30 42 FEMALE Home Maker N P 7Y III N N N N N N N N N 0.1066 P 0.6541 N P
31 60 MALE Farmer P 2W P 13Y III N P P P N N N N N 0.0334 P 0.499 N P
32 50 MALE Farmer P 10D P 6M II N P P N N N N N N 0.032 P 1.0704 N P
33 60 MALE Coolie P 1M P 10Y III N P P N N N N N N 0.0149 P 0.622 N P
34 47 FEMALE Coolie P 1W P 1Y III N N N N N N N N N 0.0257 P 0.905 N P
35 65 MALE Coolie N P 3Y III N P P N N P N N N 0.2074 P 1.0196 N P
36 54 MALE Coolie P 3D P 10Y III N P P N N N N N N 0.0607 P 0.4111 N N
37 65 FEMALE Home Maker P 3D P 4Y III N N N P N P N N N 0.0921 N 0.321 N P
38 67 MALE Farmer P 4D P 10Y III N N N N N N N N N 0.0538 P 0.6456 N N
39 65 MALE Coolie P 3W P 4Y III N P P N N P N N N 0.0477 P 1.1147 N P
40 65 MALE Farmer P 1W P 6M III N P P N N P N N N 0.0283 P 1.1574 N P
41 55 MALE Coolie N P 6Y III N P N N N P N N N 0.0596 N 0.0397 N P
42 59 MALE Coolie P 2W P 2Y III N P P N N N N N N 0.0348 P 0.9692 N P
43 37 FEMALE Home Maker P 1W P 6Y III N N N N N N N N N 0.1971 P 0.8503 P P
44 45 FEMALE Home Maker P 5D P 6M III N N N N N N N N N 0.0219 N 0.0736 N P
45 53 MALE Coolie P 5D P 20 Y III N P P N N N N N N 0.0498 N 0.2808 N N
46 67 MALE Driver N P 6M III N P P P N P N N N 0.023 P 1.0214 N P
47 54 MALE The Master P 3D P 3Y III N P P N N P N N N 0.0286 P 1.0543 N P
48 48 MALE Coolie N P 7Y III N P P N N N N N N 0.1349 P 1.1119 N P
49 65 FEMALE Home Maker N P 2Y III N N N N N N N N N 0.0361 P 1.116 N P
50 72 MALE The Master N P 2Y III N P N N N N N N N 0.034 P 0.7717 N P
